GlassScriptPhysician profile
Brooke E Breitenbach
NPI 1063661742
$5,305.39
in general payments reported to CMS, 2019-2025
25 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $957 · 2023: $1,361 · 2024: $1,234 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.95 |
| Education | $178.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,152.03 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $484.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $441.32 | 2021-2025 | |
| Ucb, INC. | $429.87 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $378.90 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $328.18 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $316.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $248.92 | 2021-2024 | Dupixent, Libtayo |
| Biofrontera INC. | $218.95 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $146.73 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.82 | 2022-2025 | Jublia, Arazlo, Duobrii |
| Incyte Corporation | $142.70 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $123.60 | 2021-2025 | Aklief, Oracea, Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $113.16 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $88.98 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $83.66 | 2021-2025 | |
| Dermavant Sciences, INC. | $74.61 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $64.94 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.01 | 2023-2024 | Cyltezo, Spevigo |
| Leo Pharma INC. | $57.50 | 2022-2023 | Adbry |
| Organon LLC | $55.24 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $47.37 | 2025 | |
| Almirall LLC | $35.94 | 2022-2023 | Seysara |
| Verrica Pharmaceuticals INC. | $35.57 | 2023-2024 | Ycanth |
| Epi Health, LLC | $32.82 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Breitenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.